Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Long-term outcomes of reduced-dose bleomycin in electrochemotherapy for basal cell carcinoma in elderly patients
Authors:ID Grošelj, Aleš (Author)
ID Jamšek, Črt (Author)
ID Kranjc Brezar, Simona (Author)
ID Čemažar, Maja (Author)
ID Omerzel, Maša (Author)
ID Pušnik, Luka (Author)
ID Serša, Gregor (Author)
Files:.pdf PDF - Presentation file, download (1,23 MB)
MD5: CEAA737C686B061EF4C459C8DB423C80
 
URL URL - Source URL, visit https://www.nature.com/articles/s41598-025-93104-3
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKC LJ - Ljubljana University Medical Centre
Abstract:Electrochemotherapy (ECT) is a minimally invasive treatment option for basal cell carcinoma (BCC), which is particularly advantageous in the elderly population. This study evaluated the long-term effects of treating BCC in older patients using ECT with a reduced dose of bleomycin (10,000 IU/m2) and compared the results to patients who received the standard dose of bleomycin (15,000 IU/m2). The retrospective analysis included 116 patients aged over 65 years with 257 histologically confirmed BCCs. Tumors were treated with either the standard dose (n = 82) or the reduced dose (n = 175) of bleomycin. The results showed that the recurrence rate was comparable between the groups, particularly in the first year after treatment. The reduced-dose group exhibited a greater recurrence rate after the first year, which may be attributed to a weaker local immune response due to the de-escalated dose of bleomycin. Nonetheless, administering a standard bleomycin dosage as a salvage treatment in the event of recurrence proved highly effective. These findings suggest that ECT with a reduced bleomycin dose is a viable option for treating BCC in elderly patients, particularly those with shorter life expectancy.
Keywords:bleomycin, electrochemotherapy, head and neck, nonmelanoma skin cancer
Publication status:Published
Publication version:Version of Record
Year of publishing:2025
Number of pages:str. 1-7
Numbering:Vol. 15, no. 1
PID:20.500.12556/DiRROS-24311 New window
UDC:616-006
ISSN on article:2045-2322
DOI:10.1038/s41598-025-93104-3 New window
COBISS.SI-ID:234048259 New window
Note:Nasl. z nasl. zaslona; Opis vira z dne 23. 4. 2025;
Publication date in DiRROS:25.11.2025
Views:441
Downloads:151
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Scientific reports
Shortened title:Sci. rep.
Publisher:Nature Publishing Group
ISSN:2045-2322
COBISS.SI-ID:18727432 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0003-2022
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0043-2020
Name:Molekularni mehanizmi razvoja in delovanja skeletne mišice

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J3-9269-2018
Name:Klinično farmakološki pristop k optimizaciji terapevtske koncentracije bleomicina zazdravljenje z elektrokemoterapijo

Funder:Other - Other funder or multiple funders
Funding programme:Univerzitetni klinični center Ljubljana
Project number:20230060
Name:Pomen hiperspektralne analize tumorjev za zdravljenje z elektrokemoterapijo

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:bleomicin, elektrokemoterapija, glava in vrat, nemelanomski rak kože


Back